MedTrace Logo

Study to Investigate Bronchial Arterrial Infusing (BAI) Plus Three-dimensional Conformal Radiotherapy (3DCRT) in Local Advanced Non-small Cell Lung Cancer (NSCLC)

NCT01201044 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2010-09-14

No results posted yet for this study

Summary

The purpose of this study is to investigate the efficacy of BAI Plus 3DCRT in local advanced NSCLC.

Conditions

Interventions

DRUG

Gemcitabine, Nedaplatin, iV

Gemcitabine, Injection, 1000mg/m2, D1 \& D7/ 4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles.

RADIATION

3DCRT

non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.

RADIATION

3DCRT

non-PD Patient will be treated with 3DCRT after 2 cycles of chemo.

DRUG

Gemcitabine，Nedaplatin, BAI

Drug: Gemcitabine, Nedaplatin, iV Gemcitabine, Injection, 1000mg/m2, D1/4weeks/cycle, 2 cycles Nedaplatin, Injection, 75mg/m2, d1/4weeks/cycle, 2 cycles. BAI

Sponsors & Collaborators

  • Third Military Medical University

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-01-31
Primary Completion
2012-09-30
Completion
2012-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01201044 on ClinicalTrials.gov